Skip to main content

Pharmacokinetics of Nitroimidazoles

  • Chapter
Nitroimidazoles

Part of the book series: NATO Advanced Study Institutes Series ((NSSA,volume 42))

  • 103 Accesses

Abstract

In this paper I want to try and show how a knowledge of the metabolism and pharmacokinetics of a compound helps us to understand the reasons why it may or may not satisfy the criteria desired of a particular drug. How we want a drug to behave depends on the use we have in mind for it. For example, in Fig. 1, are shown the plasma profiles for two nitroimidazole drugs which are used for the treatment of Trichomonas vaginalis. In this indication it is important to maintain plasma levels above the minimum inhibitory concentration (MIC) for as long a time as possible. It can be seen from the Figure that this level will be maintained longer when the compound with the longer elimination half-life, the time taken for the plasma concentration to drop to half its value, is administered. There is also the advantage that the peak levels are approximately equal for both compounds so the therapeutic ratio for ornidazole should be better than for metronidazole.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. P. Workman, Dose dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice, Cancer Chemotherapy and Pharmacology 5: 27 (1980).

    CAS  Google Scholar 

  2. S. Dische, J. F. Fowler, M. I. Saunders, M.R.L. Stratford, P. Anderson, A. Minchinton, and M. Lee, A drug for improved radiosensitization in radiotherapy, Br. J. Cancer 42: 153 (1980).

    Article  PubMed  CAS  Google Scholar 

  3. R.A.S. White, P. Workman, L.S. Freedman, L.N. Owen and N.M. Bleehen, The pharmacokinetics of misonidazole in the dog, Europ. J. Cancer 15: 1233 (1979).

    CAS  Google Scholar 

  4. R.A.S. White and P. Workman, Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-9963) in dogs, Br. J. Cancer 41: 268 (1980).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1982 Plenum Press, New York

About this chapter

Cite this chapter

Marten, T.R., Ruane, R.J., White, J.A., Clarke, L. (1982). Pharmacokinetics of Nitroimidazoles. In: Breccia, A., Cavalleri, B., Adams, G.E. (eds) Nitroimidazoles. NATO Advanced Study Institutes Series, vol 42. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-4151-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-4151-2_11

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4684-4153-6

  • Online ISBN: 978-1-4684-4151-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics